SCHEMBL2967236

SCHEMBL2967236

Cc1ccc(C(=O)Nc2cc(F)cc(N3CCCC3)c2)cc1N

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 7/20 0.50
RAB9A P51151 7/20 0.50
SMN1; SMN2 Q16637 7/20 0.50
MAPT P10636 7/20 0.50
TP53 P04637 3/20 0.50
SETD2 Q9BYW2 2/20 0.50
PLAU P00749 2/20 0.50
MAPK1 P28482 2/20 0.50
HTT P42858 2/20 0.50
TSHR P16473 1/20 0.50
ALOX15 P16050 1/20 0.50
KMT2A Q03164 4/20 0.48
MEN1 O00255 3/20 0.48
MCL1 Q07820 3/20 0.48
KDM4E B2RXH2 2/20 0.48
LMNA P02545 2/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
USP2 O75604 2/20 0.47
ALDH1A1 P00352 2/20 0.47
CNR1 P21554 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6483771 0.85 MAPK14 (0.54) NPC1RAB9ASMN1; SMN2MAPTTP53
SCHEMBL6883040 0.84 RAB9A (0.67) NPC1RAB9ASMN1; SMN2MAPTTP53
SCHEMBL10106132 0.78 CSF1R (0.66) NPC1RAB9AMAPK14
SCHEMBL4827472 0.77 RAF1 (0.64) NPC1RAB9ATP53PLAUMAPK1
SCHEMBL2977919 0.77 PLAU (0.55) NPC1RAB9ASMN1; SMN2MAPTTP53
SCHEMBL6483554 0.77 TP53 (0.55) NPC1RAB9ASMN1; SMN2MAPTTP53
SCHEMBL7151571 0.76 MEN1 (0.59) NPC1RAB9ASMN1; SMN2MAPTTP53
SCHEMBL6489471 0.76 TP53 (0.54) NPC1RAB9ASMN1; SMN2MAPTTP53
SCHEMBL22025010 0.75 KCNK3 (0.60) NPC1RAB9ASMN1; SMN2TSHRKMT2A
SCHEMBL2975048 0.74 MAPK14 (0.64) NPC1RAB9ASETD2MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7772432-B2 Amidobenzamide derivatives which are useful as cytokine inhibitors ASTRAZENECA AB (SE) 2010-08-10 US disclosed
US-20050038081-A1 Amidobenzamide derivatives which are useful as cytokine inhibitors ASTRAZENECA 2005-02-17 US disclosed
EP-1102743-A1 AMIDE DERIVATIVES WHICH ARE USEFUL AS CYTOKINE INHIBITORS AstraZeneca AB (SE) 2001-05-30 EP disclosed
WO-2000007980-A1 AMIDE DERIVATIVES WHICH ARE USEFUL AS CYTOKINE INHIBITORS ASTRAZENECA AB (SE) 2000-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038081-A1 Amidobenzamide derivatives which are useful as cytokine inhibitors IL6, IL6ST, IL2 NPC1 2786/4885RAB9A 1437/4885SMN1; SMN2 4288/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.